Segment Information (Schedule of Segment Information) (Details) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2020 |
Dec. 31, 2019 |
Dec. 31, 2018 |
|
| Segment Reporting Information [Line Items] | |||
| Net Revenue | $ 45,599,000 | $ 36,629,000 | |
| Direct cost of goods | (14,594,000) | (10,532,000) | |
| Sales and marketing costs | (17,384,000) | (17,120,000) | |
| Research and development | (64,109,000) | (81,326,000) | |
| General and administrative | (43,782,000) | (38,470,000) | |
| Other income (expense) | (8,579,000) | 9,159,000 | |
| Income tax expense | (136,000) | 0 | |
| Net loss | (102,985,000) | (101,660,000) | |
| Intangible asset, net | 14,629,000 | 7,377,000 | $ 1,417,000 |
| Tangible assets | 314,205,000 | 219,045,000 | |
| Total assets | 328,834,000 | 226,422,000 | |
| Dermatology Products Sales [Member] | |||
| Segment Reporting Information [Line Items] | |||
| Net Revenue | 44,531,000 | 34,921,000 | |
| Direct cost of goods | (14,594,000) | (10,532,000) | |
| Sales and marketing costs | (17,384,000) | (17,120,000) | |
| Research and development | 0 | 0 | |
| General and administrative | (4,716,000) | (2,556,000) | |
| Other income (expense) | (697,000) | 0 | |
| Income tax expense | (96,000) | ||
| Net loss | 7,044,000 | 4,713,000 | |
| Intangible asset, net | 14,629,000 | 7,377,000 | |
| Tangible assets | 30,843,000 | 19,946,000 | |
| Total assets | 45,472,000 | 27,323,000 | |
| Pharmaceutical and Biotechnology Product Development [Member] | |||
| Segment Reporting Information [Line Items] | |||
| Net Revenue | 1,068,000 | 1,708,000 | |
| Direct cost of goods | 0 | 0 | |
| Sales and marketing costs | 0 | 0 | |
| Research and development | (64,109,000) | (81,326,000) | |
| General and administrative | (39,066,000) | (35,914,000) | |
| Other income (expense) | (7,882,000) | 9,159,000 | |
| Income tax expense | (40,000) | ||
| Net loss | (110,029,000) | (106,373,000) | |
| Intangible asset, net | 0 | 0 | |
| Tangible assets | 283,362,000 | 199,099,000 | |
| Total assets | $ 283,362,000 | $ 199,099,000 | |
| X | ||||||||||
- Definition Tangible assets. No definition available.
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|